EMUC 2020 GU Malignancies Prostate

REVIEW UroToday

Viewing 1-16 of 16 articles

EMUC 2020: Regional Treatment of Metastasis: What For?

EMUC 2020: Oligometastatic Disease in Genitourinary Cancers: Definition and Biology

EMUC 2020: Oligometastatic Disease in Genitourinary Cancers: How Reliable is Imaging?

EMUC 2020: The Rising Star: PET CT Beyond PSMA - What You Might Not Know About Different & Upcoming Tracers

EMUC 2020: Nanoparticles in Prostate Cancer: A Perspective for the Future

EMUC 2020: Ultrasound Is Improving: 29 Mhz, mpUS, C-TRUS, Elastography and Microbubbles

EMUC 2020: Active Surveillance in Intermediate Risk Prostate Cancer

EMUC 2020: The Need for Confirmatory Biopsies in Patients on Active Surveillance Who Underwent Upfront MRI with Possible Targeted Biopsy

EMUC 2020: The Predictive Value of a Pre-Operative Negative PSMA PET/CT for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection

EMUC 2020: Multiparametric MRI Changed the World of Prostate Cancer Diagnostic: Conventional MRI, Spectroscopy, mpMRI, Diffusion Weighted Imaging

EMUC 2020: Findings from the EUPROMS Survey, Patient Reported Outcomes Study

EMUC 2020: A New Treatment Paradigm for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and BRCA1, BRCA2 or ATM Mutations, The PROfound Study

EMUC 2020: ESUP Lecture: Highlights from the Genitourinary Pathology Society (GUPS)

EMUC 2020: Who Is the Optimal Candidate for Treatment of the Primary Tumor in Oligometastic Disease?

EMUC 2020: PSMA PET for Upfront Staging in High-Risk Prostate Cancer

EMUC 2020: Germline and Mutation Testing: When and How?